COMBINATION USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR

• US 20200131270A1
• Filed: 07/19/2018
• Published: 04/30/2020
• Est. Priority Date: 07/20/2017
• Status: Active Application

• Current Assignee: FUSO Pharmaceutical Industries Limited, National University Corporation Hokkaido University
• Original Assignee: National University Corporation Hokkaido University
• Inventors: KONNAI, Satoru, OHASHI, Kazuhiko, MURATA, Shiro, OKAGAWA, Tomohiro, MAEKAWA, Naoya, NISHIMORI, Asami, GOTO, Shinya, SUZUKI, Yasuhiko, NAKAJIMA, Chie, SAJIKI, Yamato
• Application Number:
  US16/630,908
• Publication Number:
  US 20200131270A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/403 condensed with carbocyclic rings, e.g. carbazole
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/5415 ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• CPC Class Codes: A61K 31/635 having a heterocyclic ring, e.g. sulfadiazine
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/20 characterized by taxonomic origin
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/51 Complete heavy chain or Fd fragment, i.e. VH + CH1
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/70 characterized by effect upon binding to a cell or to an antigen
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor.

Claims

1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.

2. The pharmaceutical composition of claim 1, wherein the inhibitor targeting PD-1/PD-L1 is an antibody.

3. The pharmaceutical composition of claim 1, wherein the antibody is at least one antibody selected from the group consisting of anti-PD-1 antibody and anti-PD-L1 antibody.

4. The pharmaceutical composition of claim 1, wherein the COX-2 inhibitor is at least one compound selected from the group consisting of meloxicam, piroxicam, celecoxib, firocoxib, robenacoxib, carprofen and etodolac.

5. The pharmaceutical composition of claim 1 for use in prevention and/or treatment of cancer and/or infection.

6. The pharmaceutical composition of claim 1, wherein the inhibitor targeting PD-1/PD-L1 and the COX-2 inhibitor are administered separately.

7. The pharmaceutical composition of claim 1, which is a combination drug comprising the inhibitor targeting PD-1/PD-L1 and the COX-2 inhibitor.

8. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor.

9. A method of preventing and/or treating cancer and/or infection, comprising administering to a human or animal subject a pharmaceutically effective amount of a COX-2 inhibitor before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.

10. Use of a COX-2 inhibitor for preventing and/or treating cancer and/or infection, wherein the COX-2 inhibitor is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.

11. Use of a COX-2 inhibitor for use in a method of preventing and/or treating cancer and/or infection, wherein the COX-2 inhibitor is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1.